N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions

Core Insights - N2OFF, Inc. is focusing on drug discovery and solar energy investments, highlighting a new study on SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunctions [1][4] Group 1: Study Overview - The study titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction" was published on December 30, 2025, and examines the expression of 53 SLC25A genes under microgravity conditions [2] - The analysis found differential regulation of SLC25A carriers, suggesting their potential as biomarkers for mitochondrial dysfunction [3] Group 2: Company Focus and Strategy - MitoCareX Bio, a subsidiary of N2OFF, utilizes proprietary computational methods to model small-molecule modulators targeting the SLC25A family, which are crucial for cellular energy metabolism and cancer therapy resistance [4] - N2OFF owns 100% of MitoCareX Bio and has adopted a strategy focused on European renewable energy assets, currently investing in four solar projects across three EU countries [6]